Get Free Daily Intraday Tips and more >> http://www.ripplesadvisory.com/free-trial.php
India's drug pricing regulator has issued a notice seeking an explanation from companies found to be selling new versions of essential medicines without government approval on their pricing, a statement released on its website late on Wednesday showed.
The move could result in penalties for several drugmakers and is the latest in a series of recent actions by India's National Pharmaceutical Pricing Authority (NPPA) towards tightening control of drug prices.
More than 300 medicines that India defines as essential are currently under a government price cap, and the law requires companies to seek approval of the NPPA before launching new dosage forms or combinations of such drugs.
No comments:
Post a Comment